Breast Cancer Provider Interval Length in Fukushima, Japan, After the 2011 Triple Disaster: A Long-Term Retrospective Study

Akihiko Ozaki(Jyoban Hospital of Tokiwa Foundation), Hiromichi Ohira(Osaka Medical Center for Cancer and Cardiovascular Diseases), Shigeaki Kato(Fukushima Medical University), Claire Leppold(Imakiire General Hospital), Tetsuya Tanimoto(Kawasaki Medical School), Kazue Yamaoka(Teikyo University), Shigehira Saji(Fukushima Medical University), Yoshinori Nakata(Teikyo University), Shuhei Nomura(Keio University), Masaharu Tsubokura(Fukushima Medical University), Tomohiro Morita(Soma Central Hospital), Toyoaki Sawano(Jyoban Hospital of Tokiwa Foundation), Manabu Tsukada
Clinical Breast Cancer
September 6, 2019
10.1016/j.clbc.2019.07.008
Cited by 20

Related Papers

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
|The Lancet|2020|1.1k
Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images
|Gastric Cancer|2018|742
RETRACTED ARTICLE: Purification and Identification of p68 RNA Helicase Acting as a Transcriptional Coactivator Specific for the Activation Function 1 of Human Estrogen Receptor α
|Molecular and Cellular Biology|1999|358
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
|The Lancet|2022|319
Emergence Agitation After Sevoflurane Versus Propofol in Pediatric Patients
|Anesthesia & Analgesia|2000|246